Current Headlines

  1. Protalex Awarded Grant From FDA Office Of Orphan Products Development To Foster Clinical Development Of PRTX-100 For The Treatment Of Immune Thrombocytopenia
    8/17/2017

    Protalex, Inc., a clinical-stage biopharmaceutical company, announced recently that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the Company a $403,000 grant to support future clinical development activity of PRTX-100 as a treatment for Immune Thrombocytopenia (ITP)

  2. FDA Approves New Treatment For Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia
    8/17/2017

    The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

  3. Tempus Selected As Sequencing And Analytics Provider By The Prostate Cancer Clinical Trials Consortium For Phase II Clinical Trial
    8/17/2017

    Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announced today that it was selected by the Prostate Cancer Clinical Trials Consortium (PCCTC) to serve as a partner for its phase II clinical trial focused on identifying the most effective treatment for prostate cancer patients with genomic evidence of problems with DNA repair

  4. Aptevo Therapeutics And Alligator Bioscience Commence IND-Enabling Development Activities For New Bispecific Immunotherapy Candidate ALG.APV-527
    8/17/2017

    Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the companies have initiated CMC activities for the manufacturing of clinical material in preparation for a future investigational new drug (IND) submission for the bispecific immuno-oncology antibody ALG.APV-527

  5. Exelixis Submits U.S. Supplemental New Drug Application For CABOMETYX (Cabozantinib) For The Treatment Of Previously Untreated Advanced Kidney Cancer
    8/16/2017

    Exelixis, Inc. recently announced it has completed the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX (cabozantinib) tablets as a treatment for patients with previously untreated advanced renal cell carcinoma (RCC)

  6. FDA Accepts Medivir´s IND Application For MIV-711, Enabling Clinical Development In The US
    8/16/2017

    Medivir AB (Nasdaq Stockholm: MVIR) announces today that the Investigational New Drug (IND) application for MIV-711 has been accepted and the IND is now open with the FDA (U.S. Food and Drug Administration)

  7. Nanomedical Diagnostics Launches New Agile Biosensor To Accelerate Label-Free Drug Development
    8/15/2017

    Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new NHS Agile biosensor chip

  8. Metacrine Announces Collaboration On Development Of FGF1 Variants For Glucose Lowering And Improving Insulin Sensitivity
    8/15/2017

    Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it has entered a collaboration with Novo Nordisk A/S to develop Fibroblast Growth Factor 1 ("FGF1") variants for glucose lowering and insulin sensitization

  9. H3 Biomedicine Granted Orphan Drug Designation Of H3B-8800 For Treatment Of Acute Myelogenous Leukemia And Chronic Myelomonocytic Leukemia
    8/14/2017

    H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, recently announced that the U.S. Food and Drug Administration (FDA) has granted the company an orphan drug designation for H3B-8800, its lead clinical compound for the treatment of patients with Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

  10. BioreclamationIVT Acquires Biospecimen And Research Services Provider Asterand Bioscience
    8/10/2017

    BioreclamationIVT, a leading provider of biospecimens and related services, recently announced that it has acquired Asterand Bioscience, a global provider of high quality, well-characterized human tissue and research solutions with a focus on the oncology market